Inovalon Investor Conference Presentation Deck

Strong Performance In 2019... With Strong Momentum Continuing In 2020... * All numbers refer to year-over-year change to 2019 guidance as provided by the Company on October 30, 2019, unless otherwise stated. INOV Investor Presentation (1.14.20) v1.0.0 59% Primary-Source Datasets Growth to 48 Billion Medical Events, compounded annually from Q3 2016 to Q3 2019 Adj EBITDA Growth of 38% to 42% to $209M to $215M Representing a 33% Adjusted EBITDA Margin Revenue Growth of 21% to 22% On an as reported basis, with Organic Revenue Growth of 13% to 14% Operating Cash Flow increase of 44% to 60% to $130M to $145M

View entire presentation